Shandong Boan Biotechnology Co Ltd banner
S

Shandong Boan Biotechnology Co Ltd
HKEX:6955

Watchlist Manager
Shandong Boan Biotechnology Co Ltd
HKEX:6955
Watchlist
Price: 6.83 HKD 1.79%
Market Cap: HK$4.3B

Shandong Boan Biotechnology Co Ltd
Investor Relations

Shandong Boan Biotechnology Co., Ltd. operates as a biopharmaceutical company that specializes in therapeutic antibody development, manufacturing and commercialization. The company is headquartered in Yantai, Shandong and currently employs 631 full-time employees. The company went IPO on 2022-12-30. The firm is engaged in the development, production and commercialisation of therapeutic antibodies, focusing on the therapeutic areas of oncology, metabolism, autoimmunology and ophthalmology. The firm has three main technology platforms: a fully human antibody transgenic mouse and phage display technology platform, a bispecific T-cell Engager technology platform, and an antibody drug coupling (ADC) technology platform. The firm operates mainly in the domestic Chinese market and overseas markets.

Show more
Loading
6955
Hang Seng (Hong Kong)
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Ms. Hua Jiang
Executive Chairlady & CEO
No Bio Available
Dr. Changlin Dou
COO, President of R&D and Executive Director
No Bio Available
Mr. Shenghan Wang
Chief Financial Officer
No Bio Available
Mr. Jun Lu
Head of Quality Control
No Bio Available
Mr. Deyong Song
Head of Biologics Discovery Department
No Bio Available
Ms. Chunna You
Senior Vice President of R&D Center
No Bio Available
Mr. Zhou Ming
Chief Medical Officer
No Bio Available
Ms. Siu Kuen Lai FCIS, FCS
Company Secretary
No Bio Available

Contacts

Address
SHANDONG
Yantai
No. 39 Keji Avenue, High-Tech Industrial Development Zone
Contacts
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett